Selected Grants
A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (PASS)
Clinical TrialPrincipal Investigator · Awarded by Genzyme Corporation · 2016 - 2028Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis
ResearchCollaborator · Awarded by National Institute of Allergy and Infectious Diseases · 2021 - 2026MS Clinical Trial: DUOC
ResearchCo Investigator · Awarded by The Marcus Foundation · 2020 - 2025ECHO MS
Inst. Training Prgm or CMECollaborator · Awarded by National Multiple Sclerosis Society · 2023 - 2024A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2020 - 2023A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Clinical TrialPrincipal Investigator · Awarded by Biogen, Inc. · 2018 - 2021PA Fellowship in Clinical Neuroimmunology
FellowshipMentor · Awarded by Biogen, Inc. · 2017 - 2019A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2015 - 2017A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2015 - 2017External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.